BRPI0514768A - composição farmacêutica, métodos para evitar ou tratar uma doença ou condição médica hepática em um indivìduo, para inibir a proliferação de células estreladas hepáticas, para seletivamente matar as células estreladas hepática, para inibir a expressão do antìgeno de superfìcie do vìrus da hepatite b em um mamìfero, e para evitar ou tratar fibrose ou inflamação em um mamìfero, e, uso de graptopetalum ou echeveria - Google Patents
composição farmacêutica, métodos para evitar ou tratar uma doença ou condição médica hepática em um indivìduo, para inibir a proliferação de células estreladas hepáticas, para seletivamente matar as células estreladas hepática, para inibir a expressão do antìgeno de superfìcie do vìrus da hepatite b em um mamìfero, e para evitar ou tratar fibrose ou inflamação em um mamìfero, e, uso de graptopetalum ou echeveriaInfo
- Publication number
- BRPI0514768A BRPI0514768A BRPI0514768-9A BRPI0514768A BRPI0514768A BR PI0514768 A BRPI0514768 A BR PI0514768A BR PI0514768 A BRPI0514768 A BR PI0514768A BR PI0514768 A BRPI0514768 A BR PI0514768A
- Authority
- BR
- Brazil
- Prior art keywords
- graptopetalum
- mammal
- inhibiting
- stellate cells
- hepatic stellate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSIçãO FARMACêUTICA, MéTODOS PARA EVITAR OU TRATAR UMA DOENçA OU CONDIçãO MéDICA HEPáTICA EM UM INDIVìDUO, PARA INIBIR A PROLIFERAçãO DE CéLULAS ESTRELADAS HEPáTICAS, PARA SELETIVAMENTE MATAR AS CéLULAS ESTRELADAS HEPáTICA, PARA INIBIR A EXPRESSãO DO ANTìGENO DE SUPERFìCIE DO VìRUS DA HEPATITE B EM UM MAMIFERO, E PARA EVITAR OU TRATAR FIBROSE OU INFLAMAçãO EM UM MAMìFERO, E, USO DE GRAPTOPETALUM OU ECHEVERIA A presente invenção refere-se a composições compreendendo Graptopetalum e seus usos. A Graptopetalum pode proteger animais de doenças do fígado e condições médicas, tais como inflamação, esteatose e fibrose. Em particular, a Graptopetalum inibe a proliferação das células estreladas hepáticas ativadas, que representam um papel fundamental na fibrose do ligado. A Graptopetalum também tem atividades anti-fibrose, bem como inibe a proliferação dos fibroblastos dos pulmões. Portanto, além de ser um agente profilático e terapêutico para o ligado, a Graptopetalum é útil contra fibrose ou inflamação dos tecidos ou órgãos que não ligado, em particular pulmões, rins e bexiga. Outras plantas da família de Crassulaceae, particularmente Echeveria, têm efeitos similares aos da Graptopetalum.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/931,791 US7364758B2 (en) | 2004-08-31 | 2004-08-31 | Pharmaceutical use of Graptopetalum and related plants |
| PCT/CA2005/001301 WO2006024143A1 (en) | 2004-08-31 | 2005-08-29 | Pharmaceutical use of graptopetalum and related plants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0514768A true BRPI0514768A (pt) | 2008-06-24 |
Family
ID=35943513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514768-9A BRPI0514768A (pt) | 2004-08-31 | 2005-08-29 | composição farmacêutica, métodos para evitar ou tratar uma doença ou condição médica hepática em um indivìduo, para inibir a proliferação de células estreladas hepáticas, para seletivamente matar as células estreladas hepática, para inibir a expressão do antìgeno de superfìcie do vìrus da hepatite b em um mamìfero, e para evitar ou tratar fibrose ou inflamação em um mamìfero, e, uso de graptopetalum ou echeveria |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7364758B2 (pt) |
| EP (1) | EP1885381B1 (pt) |
| JP (1) | JP5058799B2 (pt) |
| KR (1) | KR100955277B1 (pt) |
| CN (1) | CN101048169B (pt) |
| AU (1) | AU2005279655B2 (pt) |
| BR (1) | BRPI0514768A (pt) |
| CA (1) | CA2578877C (pt) |
| MX (1) | MX2007002491A (pt) |
| TW (1) | TWI388332B (pt) |
| WO (1) | WO2006024143A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7588776B2 (en) * | 2004-08-31 | 2009-09-15 | Shih-Lan Hsu | Pharmaceutical use of water-soluble fraction of Graptopetalum |
| US8686030B2 (en) * | 2010-09-30 | 2014-04-01 | National Yang-Ming University | Anti-cancer extract and compounds |
| CN103393741B (zh) * | 2013-07-29 | 2016-03-30 | 嘉文丽（福建）化妆品有限公司 | 超声波辅助超临界二氧化碳连续萃取风车草叶有效成分的方法 |
| CN105813646B (zh) * | 2013-11-08 | 2020-07-28 | 黄奇英 | 一种缟办属二甲亚砜萃取物或级分之新颖用途 |
| US9474777B2 (en) | 2013-12-30 | 2016-10-25 | Development Center For Biotechnology | Plant extract and the process for treating hepatic fibrosis and liver cancer |
| EP2889037B1 (en) * | 2013-12-31 | 2019-03-27 | Development Center for Biotechnology | Plant extract and the process for treating hepatic fibrosis and liver cancer |
| JP2020513192A (ja) | 2017-03-29 | 2020-05-07 | 中国医学科学院基礎医学研究所 | 低分子ｒｎａ、並びに線維増殖性疾患及び／又は症候群の予防及び／又は治療におけるその応用 |
| CN108849993A (zh) * | 2018-08-07 | 2018-11-23 | 沂南县迎辉农业开发有限公司 | 一种防治桑树白粉病的生物药剂及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63192718A (ja) * | 1987-02-06 | 1988-08-10 | Hamari Yakuhin Kogyo Kk | 肝障害抑制剤 |
| JPH04208223A (ja) * | 1990-11-30 | 1992-07-29 | Taisho Pharmaceut Co Ltd | 肝臓疾患治療剤 |
| CN1120015C (zh) * | 1997-01-23 | 2003-09-03 | 北京君阳爱玛科技有限公司 | 高效纯天然降血糖剂 |
| JP3097997B2 (ja) * | 1997-01-23 | 2000-10-10 | キン ディン | 純天然血糖値降下剤 |
| IL126714A (en) * | 1997-02-28 | 2010-12-30 | Enzo Therapeutics Inc | Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation |
| WO2002005830A2 (en) | 2000-07-14 | 2002-01-24 | Shantaram Govind Kane | Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof |
| CN1353946A (zh) * | 2000-11-20 | 2002-06-19 | 丁庆 | 石莲花茶及其功能 |
| CN1355254A (zh) * | 2000-12-01 | 2002-06-26 | 丁庆 | 石莲花多糖 |
| JP2004026768A (ja) * | 2002-06-27 | 2004-01-29 | Kanagawa Acad Of Sci & Technol | 肝疾患治療又は予防薬 |
| JP3987793B2 (ja) * | 2002-12-27 | 2007-10-10 | 株式会社コーセー | 皮膚外用剤 |
-
2004
- 2004-08-31 US US10/931,791 patent/US7364758B2/en not_active Expired - Lifetime
-
2005
- 2005-08-29 KR KR1020077007535A patent/KR100955277B1/ko not_active Expired - Fee Related
- 2005-08-29 BR BRPI0514768-9A patent/BRPI0514768A/pt not_active IP Right Cessation
- 2005-08-29 WO PCT/CA2005/001301 patent/WO2006024143A1/en not_active Ceased
- 2005-08-29 AU AU2005279655A patent/AU2005279655B2/en not_active Ceased
- 2005-08-29 CN CN2005800292776A patent/CN101048169B/zh not_active Expired - Lifetime
- 2005-08-29 CA CA2578877A patent/CA2578877C/en not_active Expired - Fee Related
- 2005-08-29 MX MX2007002491A patent/MX2007002491A/es active IP Right Grant
- 2005-08-29 EP EP05777924.1A patent/EP1885381B1/en not_active Expired - Lifetime
- 2005-08-29 JP JP2007528535A patent/JP5058799B2/ja not_active Expired - Lifetime
- 2005-08-30 TW TW094129642A patent/TWI388332B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006024143A1 (en) | 2006-03-09 |
| MX2007002491A (es) | 2008-01-11 |
| EP1885381A1 (en) | 2008-02-13 |
| JP2008511551A (ja) | 2008-04-17 |
| US20060045925A1 (en) | 2006-03-02 |
| US7364758B2 (en) | 2008-04-29 |
| KR100955277B1 (ko) | 2010-04-30 |
| JP5058799B2 (ja) | 2012-10-24 |
| AU2005279655A1 (en) | 2006-03-09 |
| EP1885381A4 (en) | 2010-07-14 |
| CA2578877C (en) | 2013-04-30 |
| CA2578877A1 (en) | 2006-03-09 |
| AU2005279655B2 (en) | 2009-10-29 |
| CN101048169B (zh) | 2011-10-26 |
| CN101048169A (zh) | 2007-10-03 |
| HK1109581A1 (en) | 2008-06-13 |
| TW200616655A (en) | 2006-06-01 |
| KR20070083625A (ko) | 2007-08-24 |
| TWI388332B (zh) | 2013-03-11 |
| EP1885381B1 (en) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Najafi et al. | Mechanisms of inflammatory responses to radiation and normal tissues toxicity: clinical implications | |
| Afridi et al. | RETRACTED ARTICLE: Anti-hyperalgesic properties of a flavanone derivative Poncirin in acute and chronic inflammatory pain models in mice | |
| Wan et al. | Hepatoprotective and anti-hepatocarcinogenic effects of glycyrrhizin and matrine | |
| Dong et al. | Dexmedetomidine protects against ischemia–reperfusion injury in rat skeletal muscle | |
| Wang et al. | Antifibrotic activity of galangin, a novel function evaluated in animal liver fibrosis model | |
| Brocks et al. | Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| BRPI0412211A (pt) | composições de liberação controlada | |
| NO20090469L (no) | Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav | |
| BRPI0509467A (pt) | compostos macrocìclicos como inibidores de replicação viral | |
| AR055095A1 (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c | |
| WO2008073670A3 (en) | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor | |
| BRPI0412343A (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
| BRPI0515500A (pt) | derivados piridazina para inibição de estearoil-coa-desaturase | |
| NO20075245L (no) | Eliminasjon av heterogen eller blandet cellepopulasjon i tumorer | |
| DE602007004486D1 (de) | Verwendung einer hydrophilen matrix mit einem polyacrylsäurederivat, einem celluloseether und einem sprengmittel zur herstellung eines medikaments zur behandlung von erkrankungen der weiblichen genitalorgane | |
| NO20090887L (no) | Fremgangsmate for behandling og forebygging av mukositt | |
| BR112013007423A2 (pt) | terapia combinada no que diz respeito ao tratamento da infecção por hcv | |
| BRPI0514768A (pt) | composição farmacêutica, métodos para evitar ou tratar uma doença ou condição médica hepática em um indivìduo, para inibir a proliferação de células estreladas hepáticas, para seletivamente matar as células estreladas hepática, para inibir a expressão do antìgeno de superfìcie do vìrus da hepatite b em um mamìfero, e para evitar ou tratar fibrose ou inflamação em um mamìfero, e, uso de graptopetalum ou echeveria | |
| BRPI0410419A (pt) | tratamento para a ansiedade com ziprasidona | |
| Jagetia et al. | Acceleration of wound repair and regeneration by Nigella sativa in the deep dermal excision wound of mice whole body exposed to different doses of γ-radiation | |
| BRPI0607536A2 (pt) | tratamento de dor | |
| BRPI0712561B8 (pt) | Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida | |
| Bhagchandani et al. | Exploring the hepatoprotective synergy of Humulus lupulus and silymarin in mitigating liver damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |